ChinaBio Today -- Merck has offered $41.1 billion to acquire fellow big pharma Schering-Plough, an acquisition that, if completed, is expected to close in Q4 of 2009. From a China perspective, the two companies seem very similar: both market their pharmaceutical products in China, but neither one has established a major R&D presence there, nor have they been especially active in China business development projects. Will that change after the merger?
